Akt plays a pivotal role in cell survival and tumorigenesis. We investigated the potential interaction between sphingosine-1-phosphate (S1P) and platelet-derived growth factor (PDGF) in the Akt signaling pathway. Using mouse embryonic fibroblasts (MEFs) from S1P receptor knockout mice, we show here that S1P 3 was required for S473 phosphorylation of Akt by S1P. In addition, S1P-stimulated activation of Akt, but not ERK, was blocked by a PDGF receptor (PDGFR)-specific inhibitor, AG1296, suggesting a S1P 3 -mediated specific crosstalk between the Akt signaling pathways of S1P and PDGFR in MEFs. We investigated this crosstalk under different conditions and found that both Akt and ERK activation induced by S1P, but not lysophosphatidic acid (LPA), in HEY ovarian cancer cells required PDGFR but not epidermal growth factor receptor (EGFR) or insulin-like growth factor-I receptor (IGFR). Importantly, S1P induced a G i -dependent tyrosine phosphorylation of PDGFR in HEY cells. This dependence on PDGFR in S1P-induced Akt activation was also observed in A2780, T47D, and HMEC-1 cells (which express S1P 3 ), but not in PC-3 or GI-101A cells (which do not express S1P 3 ), further supporting that S1P 3 mediates the crosstalk between S1P and PDGFR. This is the first report demonstrating a unique interaction between S1P 3 and PDGFR, in addition to demonstrating a specific role for S1P 3 in S1P-induced Akt activation.
The interactions between the signaling pathways of S1P and PDGF have been shown previously in two different models: the sequential and the integrative models. Hobson et al. (22) showed a sequential model with PDGF-induced cell motility that was dependent on S1P 1 expression and an interaction between S1P 1 and PDGF that was mediated via the production of S1P in HEK293 cells and MEFs. This same group has also shown that S1P 1 appears to be dispensable for mitogenic and survival effects, even those induced by its ligand S1P and by PDGF (23) . In contrast, Alderton et al. (24) demonstrated an integrative model showing that when both PDGFR and S1P 1 were overexpressed in HEK293 cells, they formed a tethered complex, which led to more efficient stimulation of pro-mitogenic cellular events. Furthermore, they showed that tyrosine phosphorylation of G iα by PDGFR was required for efficient ERK signaling induced by either PDGF or S1P (24) . More recently this same group has provided more information on the integrative model by demonstrating that S1P acts via endogenous PDGF-β receptor-S1P 1 receptor complexes in airway smooth muscle cells to promote mitogenic signaling (25) .
In this work, we further explored the signaling mechanisms of S1P-induced Akt activation and revealed a novel type of crosstalk between S1P and PDGFR. This crosstalk is mainly mediated by S1P 3 (a S1P receptor subtype different from the previously published studies; refs [22] [23] [24] [25] and leads to Akt activation (a signaling pathway different from the cell motility and ERK activation pathways studied previously; refs [22] [23] [24] [25] . Importantly, we show here that S1P requires PDGFR to induce Akt phosphorylation in a cell type-dependent manner and S1P induces tyrosine phosphorylation of PDGFR in HEY ovarian cancer cells.
MATERIALS AND METHODS

Materials
S1P and oleoyl-LPA were purchased from Avanti Polar Lipids (Birmingham, AL) or Toronto Research Chemicals (Toronto, Canada). 18:1-LPA was dissolved in PBS, and S1P was dissolved in Tris-saline (50 mM Tris, pH 9.5, 145 mM NaCl) to 4 and 2 mM stock solutions, respectively. Pertussis toxin (PTX) was from Invitrogen (Rockville, MD), and LY294002 was from Biomol (Plymouth Meeting, PA). PDGF-BB was a kind gift from the laboratory of Dr. Paul DiCorleto, The Cleveland Clinic Foundation, and was also purchased from R&D Systems (Minneapolis, MN). EGF was from Calbiochem (La Jolla, CA), and IGF-I was a kind gift from the lab of Dr. Alan Wolfman, The Cleveland Clinic Foundation, or purchased from Calbiochem. AG1295, AG1296, AG1478, and AG1024 were obtained from Calbiochem. Neutralizing antibodies to PDGFR-α (2H7C5) and PDGFR-β (2A1E2) were kindly provided by Dr. Carol M. Sullivan, COR Therapeutics, Inc. (South San Francisco, CA). Anti-phospho-S473-Akt, anti-phospho-T308-Akt, anti-Akt, anti-phospho-ERK, and anti-ERK antibodies were obtained from Cell Signaling Technology (Beverly, MA).
Cell culture
HEY and OCC1 ovarian cancer cells were from Dr. G. Mills or Dr. R. Bast, MD Anderson (Houston, TX). T47D breast cancer cells were from ATCC (#HTB-133; Manassas, VA). GI-101A breast cancer cells were from the Goodwin Institute for Cancer Research, Inc. (Plantation, FL). An immortalized human microvascular endothelial cell line, HMEC-1 was from Centers for Disease Control and Prevention (Atlanta, GA). PC-3 prostate cancer cells were from Dr. Warren Heston, The Cleveland Clinic Foundation. All of the above cell lines were maintained in RPMI 1640 medium containing 10% fetal bovine serum (FBS). A2780 cells (also from Dr. G. Mills) were maintained in DMEM:F-12 (1:1) medium supplemented with 10% FBS. MEF wild-type, S1P 3 null, and S1P 2/3 null cells were prepared as described previously (26, 27) and maintained in DMEM with 10% FBS. All cells were cultured in serum-free media for 24-48 h before lipid treatment.
S1P 3 receptor constructs, transfection, and infection
Human cDNAs of S1P 3 were kind gifts from the laboratory of Kevin R. Lynch, University of Virginia Health System. The entire ORF of S1P 3 was PCR amplified and cloned into the p3XFLAG-CMV10 mammalian expression vector (Sigma) at the Hind III and EcoR I sites to introduce FLAG-tagged sequence into the N terminus of the receptor. The sequences of the primers used for S1P 3 are as follows: sense, 5′-TGA CAA GCT TGC AAC TGC CCT CCC G-3′, and antisense, 5′-CCG CGA ATT CAG TTG CAG AAG ATC CCA TTC-3′. The coding region of 3XFLAG-S1P 3 was PCR amplified and subcloned into the pMSCVpuro retrovirus vector (BD biosciences) at the Pme I and EcoR I sites, and the sequence of S1P 3 was confirmed by sequencing. The sequences of the primers used are as follows: sense, 5′-CCG AGT TTA AAC ATG GAC TAC AAA GAC CAT-3′, and antisense, 5′-CCG CGA ATT CAG TTG CAG AAG ATC CCA TTC-3′. The S1P 3 construct was cotransfected with an amphotropic-packaging plasmid into 293T cells with a DNA-calcium phosphate coprecipitation method. The retrovirus supernatant was harvested every 3-4 h for a total of 3 days and stored at -80°C until use. MEFs at passages 3-5 were infected. The viral supernatant supplemented with polybrene (8 µg/ml) was added to the media of the cells on 6-well plates, and the plates were centrifuged (at 700 g) at 32°C for 1 h. The cells were cultured for 12 h, and then the infections were repeated two more times. Twenty-four hours after the third infection, cells were starved from serum for 24 h before S1P or PDGF stimulation.
Nonradioactive immunoprecipitation Akt kinase assay
The Akt kinase assay was performed with the Nonradioactive Akt Kinase Assay Kit (Cell Signaling Technology) according to the instructions of the manufacturer. All reagents were provided with the kit. Briefly, cells were treated with LPA or S1P, rinsed with ice-cold phosphate-buffered saline (PBS), and then lysed in cell lysis buffer. Immunoprecipitation was carried out using immobilized Akt 1G1 monoclonal antibody. The immunoprecipitate was then incubated with GSK-3 fusion protein and ATP in kinase buffer. Western analyses were used to determine the extent of GSK-3 phosphorylation by active Akt using a phospho-GSK-3α/β (Ser21/9) antibody.
Western blot analysis
After treatment with LPA, S1P, or other stimuli, cells were rinsed with ice-cold PBS and then lysed in SDS sample buffer. Samples were electrophoresed through a 10-12% SDS polyacrylamide gel and then transferred to a PVDF membrane (Bio-Rad, Hercules, CA). Immunoblot analyses were carried out using the appropriate antibodies. Specific proteins were detected with the enhanced chemiluminescence (ECL) system (Amersham Pharmacia Biotech, Piscataway, NJ).
Determination of tyrosine phosphorylation of PDGFR
After treatment with S1P or PDGF-BB, cells were immediately placed on ice, rinsed with icecold PBS, and then lysed for 30 min on ice in 20 mM HEPES (pH 7.4) containing 0.5% Triton X-100, 150 mM NaCl, 12.5 mM β-glycerophosphate, 1.5 mM MgCl 2 , 2 mM EGTA, 10 mM NaF, 2 mM DTT, 1 mM sodium orthovanadate, 1 mM PMSF, and 20 mM aprotinin. Lysates were cleared of cellular debris by centrifugation and then precleared with protein A-Sepharose beads (Amersham Pharmacia Biotech). The lysates were then subjected to immunoprecipitation with antihuman PDGF-β receptor antibody (Santa Cruz Biotechnology, Santa Cruz, CA), and the immune complex was collected by incubation with protein A-Sepharose beads. The immunoprecipitates underwent 8% SDS-PAGE and were transferred to a PVDF membrane. The membrane was probed with antiphosphotyrosine antibody (clone 4G10; Upstate Biotechnology, Lake Placid, NY), and tyrosine phosphorylated PDGFR was detected by the ECL system.
RESULTS
S1P 3 was required for the PDGFR-dependent S473 Akt phosphorylation in MEFs
We have recently reported that both S1P and PDGF induce a MEK-dependent Akt activation only in S1P 3 -expressing cells (21) . Thus, we postulated that S1P 3 is required for the MEK (and ERK)-dependent Akt phosphorylation and proposed that a potential crosstalk exists between S1P and PDGF. To test this, we used S1P 3 null MEFs, which in addition to S1P 3 , have no endogenous expression of S1P 4 and S1P 5 but have normal expression of S1P 1 and S1P 2 (26) . In wild-type MEFs, which express S1P 1-3 , S1P (1 µM) and PDGF (10 ng/ml) induced phosphorylation of both ERK and Akt (S473) (Fig. 1A) . As expected, AG1296, a specific inhibitor of PDGFR, inhibited the phosphorylation of both Akt and ERK induced by PDGF-BB (Fig. 1A) . Interestingly, phosphorylation of Akt, but not ERK, induced by S1P was also sensitive to AG1296 (at 50 µM), suggesting that S1P requires PDGFR activity for Akt S473 phosphorylation in MEFs, while ERK phosphorylation by S1P is independent of PDGFR. On the other hand, we found that S1P was unable to induce Akt phosphorylation in S1P 3 null MEFs, but ERK activation by S1P was unaffected (Fig. 1B) . The ability of PDGF to induce phosphorylation of ERK and Akt was not significantly affected in S1P 3 null cells (Fig. 1B and E) , suggesting that PDGF was not dependent on S1P 3 to activate these downstream signaling molecules in MEFs. Reestablishment of S1P 3 expression (by infection of S1P 3 in a retroviral vector) restored the ability of S1P to induce Akt activation, which was sensitive to AG1296 (Fig. 1C) , strongly suggesting that S1P 3 is required for S473 Akt phosphorylation in MEFs, and this activity is dependent on the activation of PGDFR. We confirmed this notion in S1P 2/3 double null MEFs, where S1P was again unable to induce Akt phosphorylation, but ERK activation by S1P was unaffected (data not shown). S1P-induced Akt signaling could be restored by infecting S1P 3 alone in S1P 2/3 double null MEFs (Fig. 1D) , indicating the necessity of S1P 3 in Akt signaling and also suggesting that S1P 2 is unnecessary for the activity in MEFs. In both S1P 3 null and S1P 2/3 double null MEFs, vector-only infected cells did not change cells responsiveness to either S1P or PDGF (data not shown). Figure 1E shows the mean densitometric traces of several experiments.
S1P is dependent on PDGFR for Akt and ERK activation in HEY ovarian cancer cells
As described above, we revealed a new type of interaction between S1P and PDGFR in Akt activation in MEFs. To determine whether this interaction was also present in other cell types and to further study the nature of the interaction, we examined the PDGFR dependence of S1P-induced activation of Akt and ERK in HEY cells. HEY cells express relatively high levels of S1P 1 and S1P 3 (21) . We found that AG1296 (10 µM) pretreatment of HEY cells resulted in a complete inhibition of S1P-and PDGF-induced Akt activation (measured by an Akt enzymatic activity; Fig. 2A ). To confirm that PDGFR activity was required for the Akt activation induced by S1P, we examined the effects of AG1296, 2A1E2 (a neutralizing antibody to PDGFR-β), and 2H7C5 (a neutralizing antibody to PDGFR-α) on Akt S473 and T308 phosphorylation. We performed titration analyses of 2A1E2 and 2H7C5 to determine the optimal concentration to use in our system (data not shown). A combination of 2A1E2 and 2H7C5, both at 0.3 nM, completely blocked PDGF-BB-induced Akt activation/phosphorylation, and this concentration was used in our subsequent studies. The dependence on PDGFR activity for Akt activation was S1P specific, since a similar lipid signaling molecule, LPA, was not dependent on PDGFR for Akt phosphorylation at both S473 and T308 (Fig. 2B) . We also found that S473 phosphorylation of Akt induced by endothelin-1 and thrombin in HEY cells was not affected by pretreatment with AG1296 (data not shown). In addition, the dependence on a tyrosine kinase receptor by S1P was specific to PDGFR, since AG1478 and AG1024 (specific inhibitors of EGFR and IGFR, respectively) had no effect on S1P-induced Akt activation (Fig. 2C) .
In contrast to MEFs, we demonstrated that PDGFR was also required for ERK phosphorylation induced by S1P in HEY cells, as determined by Western blot analysis (Fig. 2D) . This is consistent with our previous observation that MEK and ERK are upstream of Akt in S1P-induced Akt activation in HEY cells (21) . These results suggest that upstream signaling mechanisms leading to Akt activation may be different in different cell types.
S1P induces tyrosine phosphorylation of PDGFR
To assess directly the involvement of PDGFR, and whether S1P could actually stimulate tyrosine phosphorylation of PDGFR, HEY cells were treated with S1P or PDGF, and tyrosine phosphorylation of PDGFR-β was assessed. As expected, PDGFR was strongly phosphorylated by PDGF (Fig. 3A) . S1P also induced phosphorylation of PDGFR, although its kinetics was slower (Fig. 3A) . Phosphorylation of PDGFR by S1P occurred as early as 1 min and maximized at 20 min (Fig. 3A) . Treatment of cells with PTX attenuated S1P-, but not PDGF-induced PDGFR tyrosine phosphorylation, suggesting that the former occurred in a G i -dependent manner and the latter did not require G i (Fig. 3B) . S1P-and PDGF-induced tyrosine phosphorylation of PDGFR was insensitive to LY294002 (Fig. 3B) , a specific inhibitor of PI3-K, indicating that PI3-K activation is not required for PDGFR phosphorylation. Furthermore, since Akt activation by S1P and PDGF requires PI3-K, it is likely that PI3-K is downstream of S1P-induced PDGFR activation in this system.
PDGFR-dependent Akt activation by S1P is cell line specific
To test whether the requirement of PDGFR activity for S1P-induced Akt activation is cell type specific, we examined Akt S473 phosphorylation in the presence or absence of AG1296 in six cancer cell lines. In addition to HEY ovarian cancer cells, S1P phosphorylated Akt in a PDGFRdependent manner in a number of other cell lines: A2780 (an ovarian cancer cell line), T47D (a breast cancer cell line), and an immortalized human microvascular endothelial cell line, HMEC-1 (Fig. 4A , and data not shown). However, in PC-3 prostate and GI-101A breast cancer cells, S1P did not require activation of PDGFR, as demonstrated by pretreatment with both AG1296 and the neutralizing antibodies against PDGFRs (Fig. 4B and data not shown) . Interestingly, we found that all PDGFR-dependent cell lines express S1P 3 and all PDGFR-independent cell lines express no or very low levels of S1P 3 (21) . These results suggest that PDGFR-dependent phosphorylation of Akt by S1P is mediated by S1P 3 specifically. Other S1P receptors, such as S1P 1 , and S1P 2 may mediate PDGFR-independent Akt activation by S1P in a cell typedependent manner.
DISCUSSION
The work presented here focuses on S1P 1 , S1P 2 , and S1P 3 , which are widely expressed. The three newly identified potential S1P receptors, gpr3, gpr6, and gpr12 are constitutively active (28) , and their role in Akt signaling remains to be investigated. Whether these receptors are expressed in MEFs has not been reported.
S1P receptor subtype-dependent Akt activation
Specific S1P receptor subtypes can regulate important physiological processes such as blood vessel maturation (7), cardiac development (8) , and angiogenesis in vivo (9) . S1P stimulates or inhibits numerous cellular functions and signaling pathways, which appear to be cell type, receptor subtype, and signaling pathway dependent, leading to different cellular functions (2, 3, 11, 12, 29) . For example, S1P stimulates and inhibits cell migration of endothelial cells and nonendothelial cells, respectively (30) . While S1P 1 and S1P 3 act as typical chemotactic receptors, S1P 2 may uniquely act as a chemorepellant receptor (31) . All three S1P receptors, S1P 1 , S1P 2 , and S1P 3 , can mediate activation of PI3-K by S1P in S1P receptor transfected CHO cells (31) . However, the downstream signaling molecules can be differentially regulated in a receptor subtype-dependent manner. It has been shown that while S1P 1 and S1P 3 positively regulate Rac, S1P 2 negatively regulates Rac, resulting in opposing effects on cell migration (31). Rosenfeldt et al. (23) showed that S1P 1 is required for cell motility but not for mitogenicity and survival effects induced by either S1P or PDGF. We have previously shown that MEFs from S1P 3 null mice show significant decreases in phospholipase C (PLC) activation, slight decreases in adenylyl cyclase inhibition, and no change in Rho activation upon S1P stimulation (26) . In contrast, S1P 2 null MEFs show a significant decrease in Rho activation but no change in PLC activation, calcium mobilization, or adenylyl cyclase inhibition. Double null (S1P 3 and S1P 2 null) MEFs displayed a complete loss of Rho activation (mediated through G 12/13 ) and a significant decrease in PLC activation and calcium mobilization (mediated via G q ), with no change in adenylyl cyclase inhibition (26, 27) . Overall, PLC activation by S1P appears to be mediated by S1P 3 . The relationship of S1P-induced PLC and Akt activation remains to be investigated.
Akt plays a very important role in cell survival and tumorigenesis. S1P 3 -mediated cell survival has been shown in rat hepatoma cells (32) but not in human umbilical vein endothelial cells (HUVEC) (9) or Schwann cells, although LPA mediates cell survival in Schwann cells through a G i -dependent Akt activation, indicating variability of signaling based on cell type examined (33) . Activation of the Akt signaling pathway by S1P has been reported in various cell types, including endothelial cells, hepatic myofibroblasts, and transfected CHO cells (16) (17) (18) 31) . With the use of an antisense approach in HUVEC, both S1P 1 and S1P 3 (which are endogenously expressed in these cells) (9) have been shown to be involved in S1P-induced NO production (34) . This activity has been related to phosphorylation of the endothelial isoform of nitric oxide synthase (eNOS) by Akt (35-37). Banno et al. (6, 19, 20) have shown that S1P 3 , when overexpressed in CHO cells, mediates Akt activation (measured by S473 phosphorylation of Akt). However, they did not address whether this activation is S1P 3 specific.
Our results not only are consistent with and support the findings of others, but we have also added important new insights to the cell type-, receptor subtype-, and signaling pathwaydependent cellular effects of S1P. We show here that S1P 3 is required for S1P-induced Akt but not ERK activation in MEFs. All other S1P receptors, including S1P 1 and S1P 2 (which are expressed in S1P 3 null MEFs), are either not sufficient or not required for Akt phosphorylation in MEFs. Since S1P 3 expression resumes the Akt activation induced by S1P in both S1P 3 null and S1P 2/3 double knockout MEFs, it suggests that S1P 2 is unnecessary for S1P-induced Akt phosphorylation in MEFs. Whether S1P 3 is sufficient for the activity remains to be addressed and will require complete removal of all other S1P receptors, including S1P 1 , S1P 2 , S1P 4 , S1P 5 , and possibly even the newly identified S1P receptors, gpr3, 6, and 12 (38) . In contrast to MEFs, we have found that S1P may be able to induce Akt phosphorylation via other S1P receptors in a number of epithelial cell lines, including a prostate cell line, PC-3, and a breast cell line, GI-101A. These cells express low or nondetectable (via quantitative PCR) levels of S1P 3 (21) . However, since these cells are not S1P 3 -"null," it cannot be ruled out that even at very low levels of expression, S1P 3 may play some role in Akt signaling. Similarly, it has been suggested that S1P 1 mediates Akt activation (measured by S473 phosphorylation) in bovine lung microvascular endothelial cells (BLMVECs). However, this conclusion was derived from the expression data (S1P 1 is highly expressed in these cells) but not functional subtype receptor based analyses. Thus, the role and involvement of each S1P receptor subtype in Akt signaling remain to be further addressed in BLMVECs.
Due to the lack of antibodies highly effective at detecting low levels of endogenous S1P receptors, almost all published work and the results presented here are based on the mRNA expression levels of these receptors, which may or may not correlate with the protein levels of these receptors in cells. More importantly, the levels of functionally active receptors cannot be easily accessed. Therefore, caution should be taken when interpreting the data presented here or in other publications. In our opinion, the work presented here using knockout MEFs provides the best evidence for the S1P 3 -mediated and PDGFR-dependent Akt activation. Antisense-and/or short-interfering RNA (siRNA)-based approaches to knock down endogenous expression of the receptor may provide useful information for the role of a particular receptor. However, complete removal of a receptor at the protein and the functional levels is hard to assess as mentioned above. Moreover, in light of a recent report on the nonspecific effects of siRNA (39) , special caution needs to be taken when using these approaches.
Nevertheless, a highly interesting finding revealed through this work is that while S1P 1 , S1P 2 , and S1P 3 all potentially mediate Akt signaling in a cell type-dependent manner, the PDGFRdependent Akt phosphorylation induced by S1P was only observed in S1P 3 -expressing (measured by the mRNA levels) cells among all cell types (fibroblasts, epithelial, or endothelial cells) tested. This suggests that among S1P 1-3 , the PDGFR-dependent Akt activation is potentially mediated by S1P 3 specifically. Together, our data, combined with the findings of others, suggest that each individual S1P receptor may have differential preferences to specific signaling pathways.
Crosstalk between S1P and PDGFR and a novel type of interaction between S1P and PDGFR
Interactions between the signaling pathways of S1P and PDGF have been shown previously in two different models as noted above. The S1P 1 -dependent PDGF action shown by Spiegel's group (22, 23) may be cell type specific, since Kluk et al. (40) have recently shown that S1P 1 was critical for S1P-induced, G i -dependent migration, but not for PDGF-BB-induced, receptor tyrosine kinase-dependent chemotaxis in vascular smooth muscle cells. The major differences between the sequential model by Spiegel's group (22, 23) and the integrative model by Pyne's group (24, 25) are that the former suggests that the production of S1P induced by PDGF is the mediator of the interaction, and PDGF is unidirectionally dependent on S1P 1 to induce cell motility, while the latter suggests that a physical interaction between S1P 1 and PDGFR, but not S1P production, plays the central role and the signaling efficiencies of both S1P and PDGF are increased (bi-directional) (Fig. 5) . In studies from Pyne's group (24, 25) , PDGF did not induce S1P production in either HEK293 or smooth muscle cells. Our work presented here adds important and interesting new information to models of interactions of S1P-PDGF signaling. We show here that 1) another S1P receptor subtype (S1P 3 , rather than S1P 1 ) is involved in the interaction between S1P and PDGF signaling; 2) a "reciprocal" requirement exists, i.e., S1P-induced Akt phosphorylation via S1P 3 requires PDGFR; and 3) S1P can activate PDGFR by induction of tyrosine phosphorylation of PDGFR (Fig. 5) . Transactivation of tyrosine kinase receptors by GPCRs has drawn a great deal of attention in recent years. Collectively, the published data and our novel observations may not necessarily be mutually exclusive and the interactions between S1P and PDGF are likely to be signaling pathway, S1P receptor subtype, and cell type specific. These interactions between S1P and PDGFR may play important physiological and pathological regulatory roles. were stimulated with S1P (1 µM) and PDGF-BB (10 ng/ml) for 10 and 5 min, respectively. Western blot analyses were performed as described in Materials and Methods using antibodies against phosphorylated Akt (p-S473-Akt), phosphorylated ERK (p-ERK), or total Akt and total ERK. AG1296 (30 min pretreatment) at concentrations indicated was used to block the PDGFR activity. B) S1P 3 null MEFs were stimulated by S1P and PDGF-BB as described above with or without AG1296 (50 µM) pretreatment. C) pMSCV-S1P 3 was infected into S1P 3 null MEFs as described in Materials and Methods. Stimulation by S1P and PDGF-BB and Western blot analyses were performed as described above. D) Same as in C except that pMSCV-S1P 3 was infected into S1P 2/3 -double null MEFs. Expression of S1P 3 was confirmed by detecting Flag-tag using an α-M2 antibody. E). Graph of mean densitometric traces of several experiments. ***P < 0.001; Student's t test. 
